Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity

Autor: Mirkka Sarparanta, Surachet Imlimthan, Iris Katariina Sokka, Filip S. Ekholm, Mikael P. Johansson, Hannu Maaheimo
Přispěvatelé: Department of Chemistry, Doctoral Programme in Chemistry and Molecular Sciences, Helsinki Institute of Sustainability Science (HELSUS)
Rok vydání: 2021
Předmět:
LINKER
Immunoconjugates
Magnetic Resonance Spectroscopy
Halogenation
Molecular Conformation
Pharmaceutical Science
auristatins
Mice
0302 clinical medicine
NMR-spectroscopy
Neoplasms
Drug Discovery
Aminobenzoates
Antibody-drug conjugates
DRUG
Cytotoxicity
Auristatins
0303 health sciences
Cytotoxins
Chemistry
Biological activity
Nuclear magnetic resonance spectroscopy
Structural characterization
Nmr-spectroscopy
Monomethyl auristatin F
317 Pharmacy
030220 oncology & carcinogenesis
Molecular Medicine
Cancer therapeutics
Oligopeptides
antibody−drug conjugates
medicine.drug
Cell Survival
Phenylalanine
antibody-drug conjugates
Antineoplastic Agents
Article
cancer therapeutics
03 medical and health sciences
Isomerism
SDG 3 - Good Health and Well-being
Cell Line
Tumor

medicine
Animals
Humans
VEDOTIN
030304 developmental biology
Combinatorial chemistry
NMR
structural characterization
PET
ANTIBODY
DISCOVERY
DOLASTATIN-10
Linker
Cis–trans isomerism
Conjugate
Zdroj: Sokka, I K, Imlimthan, S, Sarparanta, M, Maaheimo, H, Johansson, M P & Ekholm, F S 2021, ' Halogenation at the phenylalanine residue of monomethyl auristatin f leads to a favorable cis/ trans equilibrium and retained cytotoxicity ', Molecular Pharmaceutics, vol. 18, no. 8, pp. 3125-3131 . https://doi.org/10.1021/acs.molpharmaceut.1c00342
Molecular Pharmaceutics
ISSN: 1543-8392
1543-8384
Popis: Halogenation can be utilized for the purposes of labeling and molecular imaging, providing a means to, e.g., follow drug distribution in an organism through positron emission tomography (PET) or study the molecular recognition events unfolding by nuclear magnetic resonance (NMR) spectroscopy. For cancer therapeutics, where often highly toxic substances are employed, it is of importance to be able to track the distribution of the drugs and their metabolites in order to ensure minimal side effects. Labeling should ideally have a negligible disruptive effect on the efficacy of a given drug. Using a combination of NMR spectroscopy and cytotoxicity assays, we identify a site susceptible to halogenation in monomethyl auristatin F (MMAF), a widely used cytotoxic agent in the antibody-drug conjugate (ADC) family of cancer drugs, and study the effects of fluorination and chlorination on the physiological solution structure of the auristatins and their cytotoxicity. We find that the cytotoxicity of the parent drug is retained, while the conformational equilibrium is shifted significantly toward the biologically active trans isomer, simultaneously decreasing the concentration of the inactive and potentially disruptive cis isomer by up to 50%. Our results may serve as a base for the future assembly of a multifunctional toolkit for the assessment of linker technologies and exploring bystander effects from the warhead perspective in auristatin-derived ADCs.
Databáze: OpenAIRE